
Commentary|Videos|March 14, 2026
Chemotherapy vs Biomarker-Driven Models in Lymphoma
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.
Advertisement
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed the biggest hurdles in moving from standard chemotherapy to biomarker-driven models in treating patients with lymphoma.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 LAGOON Trial Fails to Confirm Survival Benefit of Lurbinectedin in Relapsed SCLC
2
The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports
3
KRAS-Mutant Lung Cancer: ASCO 2026 Highlights & Emerging Therapies
4
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
5







































